Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel
Purpose Obese patients exhibit an overall increased platelet reactivity and a reduced sensitivity to antiplatelet therapy. The aim of this study is to evaluate the platelet reactivity measured by impedance aggregometry in overweight and obese patients and chronic coronary syndrome (CCS) that were tr...
Gespeichert in:
| Veröffentlicht in: | Cardiovascular drugs and therapy 2023-08, Vol.37 (4), p.833-837 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 837 |
|---|---|
| container_issue | 4 |
| container_start_page | 833 |
| container_title | Cardiovascular drugs and therapy |
| container_volume | 37 |
| creator | Puccini, Marianna Rauch, Christian Jakobs, Kai Friebel, Julian Hassanein, Adel Landmesser, Ulf Rauch, Ursula |
| description | Purpose
Obese patients exhibit an overall increased platelet reactivity and a reduced sensitivity to antiplatelet therapy. The aim of this study is to evaluate the platelet reactivity measured by impedance aggregometry in overweight and obese patients and chronic coronary syndrome (CCS) that were treated with dual antiplatelet therapy (DAPT).
Methods
Platelet aggregation was assessed by impedance aggregometry in patients with CCS receiving DAPT (aspirin plus clopidogrel). We compared the platelet reactivity in patients with a normal weight versus overweight or obese patients. Furthermore, the correlation between the body mass index (BMI) and adenosine diphosphate- (ADP-) or thrombin receptor-activating peptide- (TRAP-) dependent platelet aggregation was analyzed.
Results
64 patients were included in the study of which 35.9% were patients with normal weight. A higher ADP- and TRAP-dependent platelet reactivity was observed in overweight and obese patients (ADP: median 27 units (U) [IQR 13–39.5] vs. 7 U [6–15],
p
|
| doi_str_mv | 10.1007/s10557-022-07325-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10397124</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2633851358</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-d1c35ed66639e6c3d0ea797f66ba69b98c598cf6dba8680469f542bee234e9ce3</originalsourceid><addsrcrecordid>eNp9kUtv1DAUhSMEotPCH2CBLLFhE_AjduIVGqY8Rqo0CJW15Tg3M64ydrCdqaa_gR9dQ9ryWLCwLPl851xfnaJ4QfAbgnH9NhLMeV1iSktcM8rLm0fFgvCalTWtyONigSXFJaNYnBSnMV7hbJKyeVqcME4JaYhcFD_eg3VbtDlAuAa73SXkA9q0EAGtI1rG6I3VCTp0bdMOaYfWzgTQMb98GbIwQEJfQZtkDzYd0TnE0SZA55Me0NIlO95DlzsIejzOOctMBetyXodWgx9t57cBhmfFk14PEZ7f3WfFt48fLlefy4vNp_VqeVGaquap7IhhHDohBJMgDOsw6FrWvRCtFrKVjeH59KJrdSMaXAnZ84q2AJRVIA2ws-LdnDtO7R46Ay4FPagx2L0OR-W1VX8rzu7U1h8UwUzWhFY54fVdQvDfJ4hJ7W00MAzagZ-iooKxhhPGm4y--ge98lNweT9Fm6rKFQnKM0VnygQfY4D-4TcEq59tq7ltldtWv9pWN9n08s89Hiz39WaAzUDMkttC-D37P7G3Wme44Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2844920625</pqid></control><display><type>article</type><title>Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Puccini, Marianna ; Rauch, Christian ; Jakobs, Kai ; Friebel, Julian ; Hassanein, Adel ; Landmesser, Ulf ; Rauch, Ursula</creator><creatorcontrib>Puccini, Marianna ; Rauch, Christian ; Jakobs, Kai ; Friebel, Julian ; Hassanein, Adel ; Landmesser, Ulf ; Rauch, Ursula</creatorcontrib><description>Purpose
Obese patients exhibit an overall increased platelet reactivity and a reduced sensitivity to antiplatelet therapy. The aim of this study is to evaluate the platelet reactivity measured by impedance aggregometry in overweight and obese patients and chronic coronary syndrome (CCS) that were treated with dual antiplatelet therapy (DAPT).
Methods
Platelet aggregation was assessed by impedance aggregometry in patients with CCS receiving DAPT (aspirin plus clopidogrel). We compared the platelet reactivity in patients with a normal weight versus overweight or obese patients. Furthermore, the correlation between the body mass index (BMI) and adenosine diphosphate- (ADP-) or thrombin receptor-activating peptide- (TRAP-) dependent platelet aggregation was analyzed.
Results
64 patients were included in the study of which 35.9% were patients with normal weight. A higher ADP- and TRAP-dependent platelet reactivity was observed in overweight and obese patients (ADP: median 27 units (U) [IQR 13–39.5] vs. 7 U [6–15],
p
< 0.001 and TRAP: 97 U [73–118.5] vs. 85 U [36–103],
p
= 0.035). Significant positive correlations were observed between agonist-induced platelet reactivity and BMI.
Conclusion
Despite the use of DAPT, a higher platelet reactivity was found in overweight and obese patients with CCS. If these patients will benefit from treatment with more potent platelet inhibitors, it needs to be evaluated in future clinical trials.</description><identifier>ISSN: 0920-3206</identifier><identifier>EISSN: 1573-7241</identifier><identifier>DOI: 10.1007/s10557-022-07325-z</identifier><identifier>PMID: 35211819</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adenosine - therapeutic use ; Adenosine diphosphate ; Adenosine Diphosphate - pharmacology ; Aspirin ; Aspirin - adverse effects ; Blood Platelets ; Body mass ; Body mass index ; Body size ; Body weight ; Cardiology ; Clinical trials ; Clopidogrel ; Clopidogrel - pharmacology ; Evaluation ; Humans ; Impedance ; Medicine ; Medicine & Public Health ; Obesity ; Obesity - diagnosis ; Obesity - drug therapy ; Overweight ; Overweight - chemically induced ; Overweight - complications ; Overweight - drug therapy ; Patients ; Platelet Aggregation ; Platelet Aggregation Inhibitors - adverse effects ; Platelet Function Tests ; Short Communication ; Therapy ; Thrombin ; Ticagrelor - pharmacology ; Ticlopidine - therapeutic use</subject><ispartof>Cardiovascular drugs and therapy, 2023-08, Vol.37 (4), p.833-837</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-d1c35ed66639e6c3d0ea797f66ba69b98c598cf6dba8680469f542bee234e9ce3</citedby><cites>FETCH-LOGICAL-c475t-d1c35ed66639e6c3d0ea797f66ba69b98c598cf6dba8680469f542bee234e9ce3</cites><orcidid>0000-0002-1544-7644</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10557-022-07325-z$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10557-022-07325-z$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35211819$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Puccini, Marianna</creatorcontrib><creatorcontrib>Rauch, Christian</creatorcontrib><creatorcontrib>Jakobs, Kai</creatorcontrib><creatorcontrib>Friebel, Julian</creatorcontrib><creatorcontrib>Hassanein, Adel</creatorcontrib><creatorcontrib>Landmesser, Ulf</creatorcontrib><creatorcontrib>Rauch, Ursula</creatorcontrib><title>Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel</title><title>Cardiovascular drugs and therapy</title><addtitle>Cardiovasc Drugs Ther</addtitle><addtitle>Cardiovasc Drugs Ther</addtitle><description>Purpose
Obese patients exhibit an overall increased platelet reactivity and a reduced sensitivity to antiplatelet therapy. The aim of this study is to evaluate the platelet reactivity measured by impedance aggregometry in overweight and obese patients and chronic coronary syndrome (CCS) that were treated with dual antiplatelet therapy (DAPT).
Methods
Platelet aggregation was assessed by impedance aggregometry in patients with CCS receiving DAPT (aspirin plus clopidogrel). We compared the platelet reactivity in patients with a normal weight versus overweight or obese patients. Furthermore, the correlation between the body mass index (BMI) and adenosine diphosphate- (ADP-) or thrombin receptor-activating peptide- (TRAP-) dependent platelet aggregation was analyzed.
Results
64 patients were included in the study of which 35.9% were patients with normal weight. A higher ADP- and TRAP-dependent platelet reactivity was observed in overweight and obese patients (ADP: median 27 units (U) [IQR 13–39.5] vs. 7 U [6–15],
p
< 0.001 and TRAP: 97 U [73–118.5] vs. 85 U [36–103],
p
= 0.035). Significant positive correlations were observed between agonist-induced platelet reactivity and BMI.
Conclusion
Despite the use of DAPT, a higher platelet reactivity was found in overweight and obese patients with CCS. If these patients will benefit from treatment with more potent platelet inhibitors, it needs to be evaluated in future clinical trials.</description><subject>Adenosine - therapeutic use</subject><subject>Adenosine diphosphate</subject><subject>Adenosine Diphosphate - pharmacology</subject><subject>Aspirin</subject><subject>Aspirin - adverse effects</subject><subject>Blood Platelets</subject><subject>Body mass</subject><subject>Body mass index</subject><subject>Body size</subject><subject>Body weight</subject><subject>Cardiology</subject><subject>Clinical trials</subject><subject>Clopidogrel</subject><subject>Clopidogrel - pharmacology</subject><subject>Evaluation</subject><subject>Humans</subject><subject>Impedance</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Obesity</subject><subject>Obesity - diagnosis</subject><subject>Obesity - drug therapy</subject><subject>Overweight</subject><subject>Overweight - chemically induced</subject><subject>Overweight - complications</subject><subject>Overweight - drug therapy</subject><subject>Patients</subject><subject>Platelet Aggregation</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Platelet Function Tests</subject><subject>Short Communication</subject><subject>Therapy</subject><subject>Thrombin</subject><subject>Ticagrelor - pharmacology</subject><subject>Ticlopidine - therapeutic use</subject><issn>0920-3206</issn><issn>1573-7241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kUtv1DAUhSMEotPCH2CBLLFhE_AjduIVGqY8Rqo0CJW15Tg3M64ydrCdqaa_gR9dQ9ryWLCwLPl851xfnaJ4QfAbgnH9NhLMeV1iSktcM8rLm0fFgvCalTWtyONigSXFJaNYnBSnMV7hbJKyeVqcME4JaYhcFD_eg3VbtDlAuAa73SXkA9q0EAGtI1rG6I3VCTp0bdMOaYfWzgTQMb98GbIwQEJfQZtkDzYd0TnE0SZA55Me0NIlO95DlzsIejzOOctMBetyXodWgx9t57cBhmfFk14PEZ7f3WfFt48fLlefy4vNp_VqeVGaquap7IhhHDohBJMgDOsw6FrWvRCtFrKVjeH59KJrdSMaXAnZ84q2AJRVIA2ws-LdnDtO7R46Ay4FPagx2L0OR-W1VX8rzu7U1h8UwUzWhFY54fVdQvDfJ4hJ7W00MAzagZ-iooKxhhPGm4y--ge98lNweT9Fm6rKFQnKM0VnygQfY4D-4TcEq59tq7ltldtWv9pWN9n08s89Hiz39WaAzUDMkttC-D37P7G3Wme44Q</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Puccini, Marianna</creator><creator>Rauch, Christian</creator><creator>Jakobs, Kai</creator><creator>Friebel, Julian</creator><creator>Hassanein, Adel</creator><creator>Landmesser, Ulf</creator><creator>Rauch, Ursula</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1544-7644</orcidid></search><sort><creationdate>20230801</creationdate><title>Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel</title><author>Puccini, Marianna ; Rauch, Christian ; Jakobs, Kai ; Friebel, Julian ; Hassanein, Adel ; Landmesser, Ulf ; Rauch, Ursula</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-d1c35ed66639e6c3d0ea797f66ba69b98c598cf6dba8680469f542bee234e9ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adenosine - therapeutic use</topic><topic>Adenosine diphosphate</topic><topic>Adenosine Diphosphate - pharmacology</topic><topic>Aspirin</topic><topic>Aspirin - adverse effects</topic><topic>Blood Platelets</topic><topic>Body mass</topic><topic>Body mass index</topic><topic>Body size</topic><topic>Body weight</topic><topic>Cardiology</topic><topic>Clinical trials</topic><topic>Clopidogrel</topic><topic>Clopidogrel - pharmacology</topic><topic>Evaluation</topic><topic>Humans</topic><topic>Impedance</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Obesity</topic><topic>Obesity - diagnosis</topic><topic>Obesity - drug therapy</topic><topic>Overweight</topic><topic>Overweight - chemically induced</topic><topic>Overweight - complications</topic><topic>Overweight - drug therapy</topic><topic>Patients</topic><topic>Platelet Aggregation</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Platelet Function Tests</topic><topic>Short Communication</topic><topic>Therapy</topic><topic>Thrombin</topic><topic>Ticagrelor - pharmacology</topic><topic>Ticlopidine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Puccini, Marianna</creatorcontrib><creatorcontrib>Rauch, Christian</creatorcontrib><creatorcontrib>Jakobs, Kai</creatorcontrib><creatorcontrib>Friebel, Julian</creatorcontrib><creatorcontrib>Hassanein, Adel</creatorcontrib><creatorcontrib>Landmesser, Ulf</creatorcontrib><creatorcontrib>Rauch, Ursula</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cardiovascular drugs and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Puccini, Marianna</au><au>Rauch, Christian</au><au>Jakobs, Kai</au><au>Friebel, Julian</au><au>Hassanein, Adel</au><au>Landmesser, Ulf</au><au>Rauch, Ursula</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel</atitle><jtitle>Cardiovascular drugs and therapy</jtitle><stitle>Cardiovasc Drugs Ther</stitle><addtitle>Cardiovasc Drugs Ther</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>37</volume><issue>4</issue><spage>833</spage><epage>837</epage><pages>833-837</pages><issn>0920-3206</issn><eissn>1573-7241</eissn><abstract>Purpose
Obese patients exhibit an overall increased platelet reactivity and a reduced sensitivity to antiplatelet therapy. The aim of this study is to evaluate the platelet reactivity measured by impedance aggregometry in overweight and obese patients and chronic coronary syndrome (CCS) that were treated with dual antiplatelet therapy (DAPT).
Methods
Platelet aggregation was assessed by impedance aggregometry in patients with CCS receiving DAPT (aspirin plus clopidogrel). We compared the platelet reactivity in patients with a normal weight versus overweight or obese patients. Furthermore, the correlation between the body mass index (BMI) and adenosine diphosphate- (ADP-) or thrombin receptor-activating peptide- (TRAP-) dependent platelet aggregation was analyzed.
Results
64 patients were included in the study of which 35.9% were patients with normal weight. A higher ADP- and TRAP-dependent platelet reactivity was observed in overweight and obese patients (ADP: median 27 units (U) [IQR 13–39.5] vs. 7 U [6–15],
p
< 0.001 and TRAP: 97 U [73–118.5] vs. 85 U [36–103],
p
= 0.035). Significant positive correlations were observed between agonist-induced platelet reactivity and BMI.
Conclusion
Despite the use of DAPT, a higher platelet reactivity was found in overweight and obese patients with CCS. If these patients will benefit from treatment with more potent platelet inhibitors, it needs to be evaluated in future clinical trials.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>35211819</pmid><doi>10.1007/s10557-022-07325-z</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-1544-7644</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0920-3206 |
| ispartof | Cardiovascular drugs and therapy, 2023-08, Vol.37 (4), p.833-837 |
| issn | 0920-3206 1573-7241 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10397124 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adenosine - therapeutic use Adenosine diphosphate Adenosine Diphosphate - pharmacology Aspirin Aspirin - adverse effects Blood Platelets Body mass Body mass index Body size Body weight Cardiology Clinical trials Clopidogrel Clopidogrel - pharmacology Evaluation Humans Impedance Medicine Medicine & Public Health Obesity Obesity - diagnosis Obesity - drug therapy Overweight Overweight - chemically induced Overweight - complications Overweight - drug therapy Patients Platelet Aggregation Platelet Aggregation Inhibitors - adverse effects Platelet Function Tests Short Communication Therapy Thrombin Ticagrelor - pharmacology Ticlopidine - therapeutic use |
| title | Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T15%3A18%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Being%20Overweight%20or%20Obese%20Is%20Associated%20with%20an%20Increased%20Platelet%20Reactivity%20Despite%20Dual%20Antiplatelet%20Therapy%20with%20Aspirin%20and%20Clopidogrel&rft.jtitle=Cardiovascular%20drugs%20and%20therapy&rft.au=Puccini,%20Marianna&rft.date=2023-08-01&rft.volume=37&rft.issue=4&rft.spage=833&rft.epage=837&rft.pages=833-837&rft.issn=0920-3206&rft.eissn=1573-7241&rft_id=info:doi/10.1007/s10557-022-07325-z&rft_dat=%3Cproquest_pubme%3E2633851358%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2844920625&rft_id=info:pmid/35211819&rfr_iscdi=true |